Publications by authors named "Isabella Demo"
Article Synopsis
- Major depressive disorder (MDD) includes a challenging subset known as treatment-resistant depression (TRD), which can be effectively targeted using rapid-acting antidepressants such as ketamine and esketamine, though individual responses vary.
- Research is focusing on identifying clinical predictors for better treatment outcomes with ketamine/esketamine, including factors like family history of alcohol use and history of childhood trauma, as well as potential brain-based biomarkers detected through EEG.
- Most response predictors show modest effects, thus future studies should employ multivariate models and standardize biomarker collection methods to improve the robustness and comparability of findings across trials.
Ketamine is an effective antidepressant, but there is substantial variability in patient response and the precise mechanism of action is unclear. Neuroimaging can provide predictive and mechanistic insights, but findings are limited by small sample sizes. This systematic review covers neuroimaging studies investigating baseline (pre-treatment) and longitudinal (post-treatment) biomarkers of responses to ketamine.
View Article and Find Full Text PDF